Sigyn Therapeutics, Inc. (SIGY)
Sigyn Therapeutics, Inc.
2468 Historic Decatur Road
Suite 140
San Diego, CA 92106
United States
619 353 0800
https://www.sigyntherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 5
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. James A. Joyce Ph.D. | Co-founder, Chairman & CEO Inventor | 486.04k | N/A | 1962 |
| Mr. Craig P. Roberts | Co-founder, CTO & Director | 256.46k | N/A | 1954 |
| Mr. Gerald DeCiccio CPA, M.B.A. | Chief Financial Officer | 128.77k | N/A | 1958 |
| Ms. Charlene R. Owen | Director of Operations | N/A | N/A | N/A |
| Dr. Annette Marleau Ph.D. | Chief Scientific Officer | N/A | N/A | 1975 |
Description
Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.
Corporate Governance
Sigyn Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
